# Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths

- Link: https://www.thailand-business-news.com/pr-news/insilico-medicine-included-in-msci-global-small-cap-indexes-gaining-capital-market-endorsement-in-core-strengths
- Published: 2026-08-17T19:30:00+07:00
- Author: PR Newswire

CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ — **Insilico Medicine ("Insilico", 
HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial
intelligence (AI)**, announced that it will be included in MSCI Global Small Cap
Indexes compiled by Morgan Stanley Capital International (MSCI). The change will
take effect as of the close of August 31, 2026.

MSCI is a global index leader, providing indexes widely tracked by global institutional
investors and passive funds as investment benchmarks. Among them, the MSCI Global
Small Cap Indexes seek to represent the performance of the diversified set of sectors
and industries among small-cap companies across both developed and emerging markets.

Insilico Medicine’s inclusion in the MSCI Global Small Cap Indexes reflects the 
capital markets’ growing endorsement of the Company’s core competitive advantages,
business model, and commercialization potential. It is expected to significantly
broaden the Company’s international visibility, attract passive capital inflows,
and improve trading liquidity.

Since its listing on the Main Board of the Hong Kong Stock Exchange on December 
30, 2025, Insilico Medicine has received research coverage from 13 leading global
brokerage firms, all with positive ratings and target prices reaching up to HKD 
100, including SWS Securities, Southwest Securities, Morgan Stanley, CITIC Securities,
Guangfa Securities, CICC, UBS, Sinolink Securities, Jefferies, HSBC, J.P. Morgan,
Guotai Haitong Securities, and Guosheng Securities.

Following its profit alert announcement on July 9, 2026, which projected H1 revenue
of USD 102.5 million to USD 106.5 million, the stock market responded with greater
confidence, represented by a research coverage number soaring by nearly 40% within
one month.

Previously, Insilico Medicine has been included into several major index series,
including the China Securities Index (CSI) Series (CSI Hong Kong Connect Innovative
Drug Index, CSI Hong Kong Brand Name Drug Index, and CSI HK Connect Health Care 
Composite Index), Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng
Biotechnology Index, FTSE Global Small Cap Index, FTSE Global All-Cap Index, and
FTSE Global Total-Cap Index.

**About Insilico Medicine**

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating
artificial intelligence and automation technologies to accelerate drug discovery,
drive innovation in the life sciences, and extend healthy longevity to people on
the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange
on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities,
Insilico is delivering innovative drug solutions for unmet needs including fibrosis,
oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico
extends the reach of Pharma. AI across diverse industries, such as advanced materials,
agriculture, nutritional products and veterinary medicine.

For more information, please visit [www.insilico.com](https://www.insilico.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths ](http://www.prnasia.com/story/archive/5027448_CN27448_0?rand=184833)
